NCT01433614View on ClinicalTrials.gov

Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

June 30, 2006

Study Completion Date

December 31, 2013

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Epirubicin

75 mg/m2 i.v. every 3 weeks, both study arms

DRUG

Paclitaxel

175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B

DRUG

Capecitabine

1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B

Trial Locations (9)

Unknown

Sahlgrenska University Hospital, Gothenburg

Helsingborg Gen. Hospital, Helsingborg

Kalmar Central Hospital, Kalmar

Karlstad Gen. Hospital, Karlstad

Linköping University Hospital, Linköping

Lund University Hospital, Lund

Malmö General University Hospital, Malmo

Sundsvall Gen. Hospital, Sundsvall

Norrland University Hospital, Umeå

All Listed Sponsors
lead

Thomas Hatschek

OTHER

NCT01433614 - Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter